Bristol’s Take On Restructuring: Cut $1.5 Bil. In Costs, Try BioPharma Model

Following a strategic review of Bristol-Myers Squibb's business, the company's management unveiled a productivity initiative Dec. 5 designed to cut $1.5 billion in costs and fashion the drug maker into a "next-generation biopharma.